Catheter Precision (NYSEAMERICAN: VTAK): The United States-based medical device company has developed the VIVO™ 3D Mapping System. The non-invasive system helps physicians identify the origin of ventricular arrhythmias prior to procedures. It also received marketing clearance from the United States FDA and boasts the CE mark. It had been designed by Catheter Precision to provide a cost-effective way of improving cardiac arrhythmia treatment. The company’s flagship technology, VIVO™, is at the basis of the system, which recorded pre-mapping accuracy to the tune of 99.5% in the detection of cardiac arrhythmias. The system is cost effective, not only cuts down on costs but is also meant to improve margins, boost outcomes and increase treatment efficiency and effectiveness for patients.
Presently, detection of ventricular arrhythmias can often be an invasive, costly, and time-consuming process if other popular means are used. Some of those means include Electrocardiogram, Echocardiogram, Cardiac Imaging, blood tests, Invasive Electrophysiological Studies, monitoring devices and study of symptoms.
Traditional methods, often require invasive procedures that can pose risks to patients and may involve longer recovery times. The non-invasive approach of the VIVO™ 3D Mapping System reduces these risks and discomfort for patients. Many of the conventional means for diagnosing ventricular arrhythmias can be costly. This includes hospitalization, specialized tests, and long-term monitoring devices. The VIVO™ system’s focus on cost-effectiveness can be a significant advantage, making cardiac arrhythmia diagnosis and treatment more accessible to a broader patient population.
The VIVO™ system’s speed and accuracy in detecting cardiac arrhythmias are crucial factors. Timely diagnosis is essential in managing heart conditions, and the non-invasive 3D mapping system offers a quicker path to diagnosis, allowing for immediate treatment or intervention. Non-invasive procedures are generally more comfortable for patients, which can improve patient compliance and overall satisfaction with the healthcare experience. By offering an all-in-one solution with high accuracy, the VIVO™ 3D Mapping System may reduce the need for multiple diagnostic tests and procedures. This can streamline the diagnostic process, saving time and resources for both patients and healthcare providers. The accurate diagnosis provided by the VIVO™ system can potentially lead to better treatment outcomes and improved patient care.
While the VIVO™ 3D Mapping System shows promise, it’s essential for healthcare professionals and regulatory bodies to thoroughly evaluate its performance, safety, and effectiveness. Moreover, the market’s acceptance and adoption of this technology will be critical for its success. As with any medical innovation, continued research and real-world clinical experience will play a role in determining its long-term impact on the diagnosis and treatment of ventricular arrhythmias.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com